Shire signs NPS Pharma acquisition deal

Shire has announced the acquisition of NPS Pharma, a rare disease-focused biopharmaceutical company, in a deal worth $5.2 billion (3.42 billion pounds).

This merger aims to accelerate the growth of NPS Pharma's innovative portfolio via its proven expertise in gastrointestinal disorders, core capabilities in rare disease patient management and global footprint. 

NPS Pharma's first product, known as Gattex/Revestive, is approved in the US and Europe as a treatment adults with short bowel syndrome who are dependent on parenteral support. It also has a registration phase product, Natpara/Natpar, for the treatment of hypoparathyroidism.

The takeover will help Shire strengthen its position as a leading biotechnology firm, as well as broadening its expertise in the field of rare diseases.

Dr Flemming Ornskov, Shire's chief executive officer, said: "We look forward to accelerating the growth of the NPS Pharma portfolio, based on our proven track record of maximising value from acquired assets and commercial execution."

This is the first major acquisition activity Shire has engaged in since it agreed to terminate its planned merger with AbbVie last October.